CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Survival advantage of native and engineered T cells is acquired by mitochondrial transfer from mesenchymal stem cells.
Survival advantage of native and engineered T cells is acquired by mitochondrial transfer from mesenchymal stem cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
人工 MitoT 通过干扰 caspase 通路阻止 STS 诱导的人 CD3+ T 细胞凋亡。此外,我们观察到 MitoT 对 MitoT pos CAR-T 工程化细胞中电穿孔诱导的凋亡具有保护作用,可能改善其代谢适应性及对环境应激的抵抗能力。这些结果拓宽了基于细胞器的疗法在免疫疾病中的生理学前景,同时为在 CAR-T 治疗中细胞活力受损时提升治疗结局提供了潜在途径。
细胞凋亡是一种程序性细胞死亡形式,对免疫系统的发育和稳态至关重要。CAR-T(CAR-T)细胞疗法已获批用于血液系统恶性肿瘤,但仍存在与体外操作相关的若干局限性和挑战,包括CAR-T 细胞对凋亡的易感性。因此,需要提高T细胞存活和持续存在的策略。间充质干/基质细胞(MSCs)具有免疫调节和组织修复潜能。我们此前已表明,转移脐带MSC(UC-MSC)来源的线粒体(MitoT)可促使CD3+ T细胞发生基因重编程,向T reg细胞谱系转化。T细胞的效力在有效免疫治疗中发挥重要作用,凸显了改善其代谢适应性的必要性。在本研究中,我们评估MitoT对天然T淋巴细胞和工程化CAR-T 细胞凋亡的影响。
我们采用了一种无细胞方法,利用UC-MSC来源的MT通过人工MitoT(Mitoception)导入外周血单个核细胞(PBMCs),随后对分选出的CD3+ MitoT pos和MitoT neg细胞进行RNA-seq分析。用Staurosporine(STS)诱导靶细胞凋亡,并通过Annexin V/7AAD和TUNEL检测评估细胞活力。通过流式细胞术、western blot和qRT-PCR评估凋亡调节因子的变化。通过Annexin V/7AAD评估MitoT对19BBz CAR-T 细胞在电穿孔非病毒转座子载体后凋亡反应的影响。
Mitoception后,CD3+ T细胞中与凋亡、细胞死亡和/或对不同刺激的反应相关的基因表达发生了改变。与MitoT neg细胞相比,CD3+ MitoT pos细胞对STS诱导的凋亡具有抗性,表现为凋亡T细胞百分比以及TUNEL+细胞百分比降低。此外,MitoT阻止了STS诱导的线粒体膜电位(MMP)水平崩溃,降低了caspase-3切割,并在FACS分选的CD3+ T细胞中增加了BCL2转录本水平和BCL-2相关的BARD1表达。此外,UC-MSC来源的MitoT减少了电转后CAR-T 细胞的早期和晚期凋亡,并表现出细胞毒性活性水平升高的趋势。
Apoptosis, a form of programmed cell death, is critical for the development and homeostasis of the immune system. Chimeric antigen receptor T (CAR-T) cell therapy, approved for hematologic cancers, retains several limitations and challenges associated with ex vivo manipulation, including CAR T-cell susceptibility to apoptosis. Therefore, strategies to improve T-cell survival and persistence are required. Mesenchymal stem/stromal cells (MSCs) exhibit immunoregulatory and tissue-restoring potential. We have previously shown that the transfer of umbilical cord MSC (UC-MSC)-derived mitochondrial (MitoT) prompts the genetic reprogramming of CD3 + T cells towards a T reg cell lineage. The potency of T cells plays an important role in effective immunotherapy, underscoring the need for improving their metabolic fitness. In the present work, we evaluate the effect of MitoT on apoptotis of native T lymphocytes and engineered CAR-T cells.
We used a cell-free approach using artificial MitoT (Mitoception) of UC-MSC derived MT to peripheral blood mononuclear cells (PBMCs) followed by RNA-seq analysis of CD3 + MitoT pos and MitoT neg sorted cells. Target cell apoptosis was induced with Staurosporine (STS), and cell viability was evaluated with Annexin V/7AAD and TUNEL assays. Changes in apoptotic regulators were assessed by flow cytometry, western blot, and qRT-PCR. The effect of MitoT on 19BBz CAR T-cell apoptosis in response to electroporation with a non-viral transposon-based vector was assessed with Annexin V/7AAD.
Gene expression related to apoptosis, cell death and/or responses to different stimuli was modified in CD3 + T cells after Mitoception. CD3 + MitoT pos cells were resistant to STS-induced apoptosis compared to MitoT neg cells, showing a decreased percentage in apoptotic T cells as well as in TUNEL + cells. Additionally, MitoT prevented the STS-induced collapse of the mitochondrial membrane potential (MMP) levels, decreased caspase-3 cleavage, increased BCL2 transcript levels and BCL-2-related BARD1 expression in FACS-sorted CD3 + T cells. Furthermore, UC-MSC-derived MitoT reduced both early and late apoptosis in CAR-T cells following electroporation, and exhibited an increasing trend in cytotoxic activity levels.
Artificial MitoT prevents STS-induced apoptosis of human CD3 + T cells by interfering with the caspase pathway. Furthermore, we observed that MitoT confers protection to apoptosis induced by electroporation in MitoT pos CAR T-engineered cells, potentially improving their metabolic fitness and resistance to environmental stress. These results widen the physiological perspective of organelle-based therapies in immune conditions while offering potential avenues to enhance CAR-T treatment outcomes where their viability is compromised.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。